<DOC>
	<DOCNO>NCT00448864</DOCNO>
	<brief_summary>The primary objective study assess efficacy safety 2 dose level ecallantide versus placebo reduce blood loss follow cardiopulmonary bypass ( CPB ) , measure chest tube drainage first 12 hour postoperatively chest tube remove , whichever come first , patient undergo primary coronary artery bypass grafting ( CABG ) , single valve repair , single valve replacement . The secondary objective compare efficacy ecallantide-treated participant ( pool high low-doses ) placebo compare high-dose low-dose ecallantide group . Other secondary objective evaluate pharmacokinetics antibody formation .</brief_summary>
	<brief_title>Efficacy Study Recombinant Protein ( Ecallantide ) Reduce Blood Loss During Primary Coronary Bypass Grafting Valve Repair/Replacement</brief_title>
	<detailed_description>This Phase 2 , randomize , double-blind , placebo-controlled , multi-center study design ass efficacy safety 2 dose level ecallantide compare placebo reduce chest tube drainage participant require CPB primary CABG , single valve repair , single valve replacement . Participants randomize 3:3:2 ratio ecallantide high-dose regimen ( maximum 91 mg ) , ecallantide low-dose regimen ( maximum 15 mg ) , placebo . Randomization stratify surgical procedure participant undergo valve replacement would evenly distribute across treatment arm . Each participant receive active drug placebo administer stage day surgical procedure induction anesthesia ( Day 1 ) . Participants screen 14 day prior surgery . Additional study procedure conduct Day -1 1 , peri-operatively , immediate postoperative period , Days 2 , 4 , 7 ( time discharge hospital ) , Days 28 43 ( follow-up ) .</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Blood Loss , Surgical</mesh_term>
	<criteria>Men woman ≥18 ≤85 year age Elective primary coronary artery bypass grafting ( CABG ) , single valve repair , single valve replacement require CPB full sternotomy No plan use desmopressin acetate ( DDAVP ) , atrial natriuretic hormone , Eaminocaproic acid ( EACA ) , tranexamic acid , aprotinin postoperatively Female participant must nonlactating pregnant If childbearing potential , female participant must agree use adequate contraception 1 month receive study drug Concomitant surgery include limited atrial septal defect repair , multiple valve replacement , carotid endarterectomy , combine CABG valve procedure Planned hypothermic CPB use temperature less 28 degree Celsius Weight &lt; 55 kilogram ( kg ) Major end organ dysfunction , define : Cardiac : Left ventricular ejection fraction ( LVEF ) &lt; 30 % leave ventriculography , echocardiogram , catheterization ( within 90 day prior screen ) Use positive IV inotropic agent within 12 hour prior surgery Preoperative use intraaortic balloon pump ( IABP ) , leave ventricular assist device ( LVAD ) , extracorporeal membrane oxygenation ( ECMO ) Renal : Serum creatinine &gt; 1.5 milligram per deciliter ( mg/dL ) Hepatic : Aspartate aminotransferase ( AST ) alanine transferase ( ALT ) &gt; 2.5 x upper limit normal Hematologic : Preoperative hematocrit ( Hct ) &lt; 30 % Platelet count &lt; 100,000/mm^3 Planned transfusion surgical procedure History family history bleed clot disorder ( example , von Willebrand 's Disease , idiopathic thrombocytopenia purpura ( ITP ) , thrombotic thrombocytopenia purpura ( TTP ) , hematologic malignancy ) Prothrombin time ( PT ) activate partial thromboplastin time ( aPTT ) &gt; 1.5 x normal range ; receive unfractionated heparin preoperatively , abnormal preoperative PT/aPTT permit Serious intercurrent illness active infection Previous exposure ecallantide Known allergy ecallantide component , fentanyl , midazolam , isoflurane , propofol , morphine , heparin , protamine Autologous blood donation ≤ 30 day month prior surgery Known substance abuse within 6 month prior surgery Receipt investigational drug device within 30 day prior participation current study Administration : Eptifibatide &lt; 12 hour prior surgery Tirofiban hydrochloride ( HCl ) &lt; 12 hour prior surgery Enoxaparin sodium low molecularweight heparin &lt; 24 hour prior surgery Clopidogrel &lt; 5 day prior surgery Warfarin &lt; 5 day prior surgery ( Warfarin must discontinue 5 day prior surgery PT must &lt; 18 second ) Ticlopidine &lt; 7 day prior surgery Abciximab &lt; 24 hour prior surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>